Stocktoria
Sarepta Therapeutics, Inc. SRPT
Sarepta Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2B | $1.9B | $1.2B | $933.0M | $701.9M | $540.1M | $380.8M | $301.0M | $154.6M | $5.4M |
| R&D expense | — | — | — | — | — | — | — | $401.8M | $166.7M | $188.3M |
| SG&A expense | $491.7M | $557.9M | $481.9M | $451.4M | $282.7M | $317.9M | $284.8M | $207.8M | $122.7M | $83.7M |
| Operating income | -$699.8M | $218.1M | -$267.8M | -$536.2M | -$459.7M | -$564.2M | -$705.6M | -$343.6M | -$171.6M | -$266.7M |
| Interest expense | -$38.1M | -$18.4M | -$22.0M | -$53.2M | $63.5M | $59.9M | $30.7M | $33.7M | $5.8M | $1.9M |
| Income tax | $11.2M | $25.5M | $15.9M | $13.5M | -$168,000 | $1.1M | $1.2M | -$692,000 | $2.1M | — |
| Net income | -$713.4M | $235.2M | -$536.0M | -$703.5M | -$418.8M | -$554.1M | -$715.1M | -$361.9M | -$50.7M | -$267.3M |
| EPS (diluted) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | — | — | — | — |
| Operating cash flow | -$205.5M | -$205.8M | -$501.0M | -$325.3M | -$443.2M | $107.5M | -$456.5M | -$388.7M | -$232.0M | -$245.8M |
| Free cash flow | -$307.5M | -$342.7M | -$577.1M | -$356.2M | -$481.7M | $25.3M | -$516.1M | -$449.8M | -$244.0M | -$251.2M |
| Cash & equivalents | $801.3M | $1.1B | $428.4M | $966.8M | $2.1B | $1.5B | $835.1M | $370.8M | $599.7M | $122.4M |
| Inventory | $914.7M | $750.0M | $322.9M | $204.0M | $186.2M | $232.0M | $171.4M | $125.4M | $83.6M | $12.8M |
| Total assets | $3.3B | $4.0B | $3.3B | $3.1B | $3.1B | $3.0B | $1.8B | $1.6B | $1.3B | $424.1M |
| Total liabilities | $2.2B | $2.4B | $2.4B | $2.7B | $2.2B | $2.2B | $1.0B | $609.8M | $518.7M | $87.4M |
| Shareholders' equity | $1.1B | $1.5B | $859.3M | $384.9M | $928.0M | $761.8M | $818.2M | $1.0B | $789.2M | $336.7M |
Growth · year-over-year · Revenue CAGR 94.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +15.6% | +53.0% | +33.3% | +32.9% | +30.0% | +41.8% | +26.5% | +94.7% | +2751.6% | +332.6% |
| Net income growth | -403.3% | — | — | — | — | — | — | — | — | — |
| EPS growth | -404.7% | — | — | — | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | — | -2006.5% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.